Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
2.
Neuroscience ; 134(3): 1057-68, 2005.
Article in English | MEDLINE | ID: mdl-15979808

ABSTRACT

Recent studies have revealed systematic differences in the pyramidal cell structure between functionally related cortical areas of primates. Trends for a parallel in pyramidal cell structure and functional complexity have been reported in visual, somatosensory, motor, cingulate and prefrontal cortex in the macaque monkey cortex. These specializations in structure have been interpreted as being fundamental in determining cellular and systems function, endowing circuits in these different cortical areas with different computational power. In the present study we extend our initial finding of systematic specialization of pyramidal cell structure in sensory-motor cortex in the macaque monkey [Cereb Cortex 12 (2002) 1071] to the vervet monkey. More specifically, we investigated pyramidal cell structure in somatosensory and motor areas 1/2, 5, 7, 4 and 6. Neurones in fixed, flat-mounted, cortical slices were injected intracellularly with Lucifer Yellow and processed for a light-stable 3,3'-diaminobenzidine reaction product. The size of, number of branches in, and spine density of the basal dendritic arbors varied systematically such that there was a trend for increasing complexity in arbor structure with progression through 1/2, 5 and 7. In addition, cells in area 6 were larger, more branched, and more spinous than those in area 4.


Subject(s)
Motor Cortex/cytology , Pyramidal Cells/cytology , Somatosensory Cortex/cytology , Animals , Cell Count , Cell Shape , Cell Size , Chlorocebus aethiops , Dendritic Spines , Indoles/metabolism , Male
3.
Lett Appl Microbiol ; 40(3): 172-7, 2005.
Article in English | MEDLINE | ID: mdl-15715640

ABSTRACT

AIMS: The objective of this study was to identify compounds responsible for medicinal off-flavours produced by different species and strains of Alicyclobacillus in orange juice using a combination of chromatographic-coupled olfactometric techniques and gas chromatography-mass spectrometry (GC-MS). METHODS AND RESULTS: Each of five Alicyclobacillus strains was inoculated into separate juice samples and incubated up to 28 days at 45 degrees C. Aroma compounds in the juice were analysed by GC-olfactometry (GC-O) and confirmed using GC-MS. GC-O identified three components that were described as medicinal/antiseptic. Microbial populations were enumerated at timed intervals by spiral plating onto Alicyclobacillus agar. Within 28 days incubation, all five strains produced medicinal off-aromas from guaiacol and at least one halogenated phenol. SIGNIFICANCE AND IMPACT OF THE STUDY: This is the first study to evaluate individual juice aroma components produced by Alicyclobacillus species using olfactometry and to demonstrate that at least three medicinal off-flavour compounds are associated with the growth of alicyclobacilli in orange juice.


Subject(s)
Beverages/microbiology , Chromatography, Gas/methods , Citrus/microbiology , Food Microbiology , Gram-Positive Endospore-Forming Bacteria/metabolism , Odorants , Beverages/analysis , Gas Chromatography-Mass Spectrometry , Guaiacol/analysis , Guaiacol/metabolism , Phenols/analysis , Phenols/metabolism
4.
Am J Respir Cell Mol Biol ; 24(5): 599-607, 2001 May.
Article in English | MEDLINE | ID: mdl-11350830

ABSTRACT

Tissue inhibitors of metalloproteinases (TIMPs) are multifunctional proteins that have the capacity to modify cellular activities and to modulate matrix turnover. We demonstrate that TIMP-1 messenger RNA (mRNA) and protein expression are selectively and markedly increased in a murine model of bleomycin-induced pulmonary fibrosis. Northern analysis showed that lung steady-state TIMP-1 mRNA levels increased 14-fold after bleomycin administration compared with control mice. Expression of the genes for TIMP-2, TIMP-3, and interstitial collagenase (matrix metalloproteinase-13) was unaltered in the injured lung. In situ hybridization demonstrated that TIMP-1 gene induction was spatially restricted to areas of lung injury. Metalloproteinase inhibitory activity of relative molecular mass of ~ 21 to 28 kD, corresponding to the molecular weights for TIMP-1 and TIMP-2, was identified in lung extracts of bleomycin-injured mice by reverse zymography. Western analysis demonstrated that TIMP-1 protein levels in bronchoalveolar lavage fluid (BALF) of bleomycin-treated mice increased 220- and 151-fold at Days 4 and 28, respectively, compared with control mice. TIMP-2 immunoreactive protein in the BALF increased 20- and 103-fold relative to controls at Days 4 and 28, respectively. These results demonstrate that TIMP-1 gene expression is selectively increased, and that the expression of TIMP-1 and TIMP-2 is differentially regulated in bleomycin-induced pulmonary fibrosis. The profound and durable increase in TIMP-1 and TIMP-2 proteins suggests an important regulatory role for these antiproteases in the inflammatory and fibrotic responses to bleomycin-induced lung injury.


Subject(s)
Pulmonary Fibrosis/metabolism , RNA, Messenger/biosynthesis , Tissue Inhibitor of Metalloproteinase-1/biosynthesis , Animals , Bleomycin , Bronchoalveolar Lavage Fluid/chemistry , Collagenases/genetics , Collagenases/metabolism , Disease Models, Animal , Immunohistochemistry , In Situ Hybridization , Lung/metabolism , Lung/pathology , Male , Matrix Metalloproteinase 13 , Mice , Procollagen/genetics , Procollagen/metabolism , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/pathology , Tissue Inhibitor of Metalloproteinase-1/analysis , Tissue Inhibitor of Metalloproteinase-1/genetics , Tissue Inhibitor of Metalloproteinase-2/analysis , Tissue Inhibitor of Metalloproteinase-2/biosynthesis , Tissue Inhibitor of Metalloproteinase-2/genetics , Tissue Inhibitor of Metalloproteinase-3/biosynthesis , Tissue Inhibitor of Metalloproteinase-3/genetics
5.
Am J Respir Cell Mol Biol ; 20(5): 924-34, 1999 May.
Article in English | MEDLINE | ID: mdl-10226062

ABSTRACT

Despite evidence that implicates transforming growth factor-alpha (TGF-alpha) in the pathogenesis of acute lung injury, the contribution of TGF-alpha to the fibroproliferative response is unknown. To determine whether the development of pulmonary fibrosis depends on TGF-alpha, we induced lung injury with bleomycin in TGF-alpha null-mutation transgenic mice and wild-type mice. Lung hydroxyproline content was 1.3, 1.2, and 1.6 times greater in wild-genotype mice than in TGF-alpha-deficient animals at Days 10, 21, and 28, respectively, after a single intratracheal injection of bleomycin. At Days 7 and 10 after bleomycin treatment, lung total RNA content was 1.5 times greater in wild-genotype mice than in TGF-alpha-deficient animals. There was no significant difference between mice of the two genotypes in lung total DNA content or nuclear labeling indices after bleomycin administration. Wild-genotype mice had significantly higher lung fibrosis scores at Days 7 and 14 after bleomycin treatment than did TGF-alpha-deficient animals. There was no significant difference between TGF-alpha-deficient mice and wild-genotype mice in lung inflammation scores after bleomycin administration. To determine whether expression of other members of the epidermal growth factor (EGF) family is increased after bleomycin-induced injury, we measured lung EGF and heparin-binding- epidermal growth factor (HB-EGF) mRNA levels. Steady-state HB-EGF mRNA levels were 321% and 478% of control values in bleomycin-treated lungs at Days 7 and 10, respectively, but were not significantly different in TGF-alpha-deficient and in wild-genotype mice. EGF mRNA was not detected in normal or bleomycin-treated lungs of mice of either genotype. These results show that TGF-alpha contributes significantly to the pathogenesis of pulmonary fibrosis after bleomycin-induced injury, and that compensatory increases in other EGF family members do not occur in TGF-alpha-deficient mice.


Subject(s)
Pulmonary Fibrosis/genetics , Transforming Growth Factor alpha/deficiency , Animals , Base Sequence , Bleomycin/toxicity , Cell Division , Collagen/metabolism , DNA/metabolism , DNA Primers , Epidermal Growth Factor/genetics , Genotype , Heparin-binding EGF-like Growth Factor , Intercellular Signaling Peptides and Proteins , Lung/cytology , Lung/drug effects , Lung/metabolism , Mice , Mice, Knockout , Mice, Transgenic , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/pathology , RNA/metabolism , Transforming Growth Factor alpha/genetics
6.
Anaesthesia ; 49(3): 188-9, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8147507

ABSTRACT

The metabolism of many drugs is abnormal in the critically ill patient. The causes of this are unknown, and investigation in patients is difficult. We therefore used isolated, cultured human hepatocytes to study the effects of hypoxia and induction on cytochrome P450 3A, the cytochrome responsible for the metabolism of many drugs. When hepatocytes were exposed to 5% oxygen, the amount of 3A produced, after induction with rifampicin, was five to 10 times less than the amount produced in 21% oxygen. In another study, we exposed isolated hepatocytes for 4 days to serum from five critically ill patients or from volunteers. At the end of this time, the functional ability of the hepatocytes to glucuronidate 14C progesterone was measured. Four of the five patients had a substance in their plasma that reduced the ability of the hepatocytes to glucuronidate progesterone. The nature of this substance and the reason that the serum from the fifth patient did not affect metabolism are unknown. This model is able to simulate the abnormalities which occur in critically ill patients. Further studies are needed to explain our observations and to identify the substances in the serum from critically ill patients that alter drug metabolism.


Subject(s)
Adenoma/metabolism , Aryl Hydrocarbon Hydroxylases , Liver Neoplasms/metabolism , Liver/metabolism , Pharmaceutical Preparations/metabolism , Adenoma/blood , Adult , Aged , Cell Hypoxia/physiology , Cells, Cultured , Colonic Neoplasms/pathology , Critical Illness , Cytochrome P-450 CYP2E1 , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme System/biosynthesis , Enzyme Induction , Female , Humans , Liver Neoplasms/blood , Liver Neoplasms/secondary , Male , Middle Aged , Oxidoreductases, N-Demethylating/biosynthesis , Progesterone/metabolism , Severity of Illness Index
7.
Anaesthesia ; 49(1): 17-20, 1994 Jan.
Article in English | MEDLINE | ID: mdl-7508691

ABSTRACT

The aim of this in-vitro study was to investigate the incidence of propofol agglutination with serum from critically ill patients. Serum (400 microliters) from 58 critically ill patients and 30 healthy volunteers was incubated with 10 microliters of either propofol, Intralipid 10% or Intralipid 20%. Control incubations contained serum only. At 24 h, the serum was examined macroscopically and microscopically for agglutination. Agglutination was seen with Intralipid 20% in serum from all critically ill patients and 13.3% of volunteers. Serum from 91.4% of critically ill patients was agglutinated with Intralipid 10% and only 3.3% of the healthy volunteers. In comparison, propofol produced agglutination in 74.1% of critically ill patients and in none of the serum from healthy volunteers (p < 0.05 propofol versus Intralipid 10%, p < 0.0001 propofol versus Intralipid 20%). No correlation was seen between agglutination and age, sex, APACHE II score or plasma concentration of acute phase proteins. However, agglutination of propofol and Intralipid 10% was more frequent (p < 0.001) in serum from patients with pulmonary disease, than in patients with normal lungs. The clinical implications of these in-vitro findings are unclear and need further investigation.


Subject(s)
Anesthesia, Intravenous , Critical Illness , Fat Emulsions, Intravenous/pharmacology , Hemagglutination/drug effects , Propofol/pharmacology , Acute-Phase Proteins/analysis , Adult , Aged , Dose-Response Relationship, Drug , Emulsions , Fat Emulsions, Intravenous/administration & dosage , Female , Humans , Lung Diseases/blood , Male , Middle Aged , Phospholipids , Pilot Projects , Prospective Studies , Single-Blind Method , Soybean Oil
11.
J Perinat Med ; 18(3): 157-63, 1990.
Article in English | MEDLINE | ID: mdl-2117060

ABSTRACT

C. reactive protein (CRP) estimations were performed prospectively on 30 consecutive admissions of very low birth weight infants to a Regional neonatal intensive care unit. The samples were analysed by a recently described, rapid intralipid agglutination assay and by a reference turbidimetric technique. Two hundred and ninety samples were assayed by both techniques. The intralipid agglutination was positive on two occasions when the reference method found normal levels. No false negative reactions occurred. Bacterial micro-organisms were isolated on 32 occasions but 19 of the organisms were considered to represent bacterial colonisation or contamination. The CRP remained negative in 17 cases. There were 13 episodes of clinical deterioration associated with positive bacterial cultures. In each of the six infants with severe systemic infections (septicaemia (4), meningitis (1), and osteomyelitis (1)), the levels were raised. In five of these infants the CRP was elevated before, or at the time of, the clinical deterioration. The CRP remained normal during seven (54%) of the culture positive events. We believe that the CRP estimations provide additional information in the evaluation of the infant with suspected sepsis. Serial measurements are helpful in distinguishing bacterial contamination from invasive infection but are not helpful in predicting infection during the pre-clinical phase. The intralipid agglutination technique is a rapid and reliable test and could be performed on the neonatal unit outside normal laboratory hours.


Subject(s)
Acute-Phase Reaction/blood , Bacterial Infections/diagnosis , C-Reactive Protein/metabolism , Infant, Low Birth Weight , Inflammation/blood , Agglutination Tests , Bacterial Infections/blood , False Positive Reactions , Humans , Infant, Newborn , Prospective Studies , Risk Factors
12.
J Pediatr ; 103(2): 228-32, 1983 Aug.
Article in English | MEDLINE | ID: mdl-6410033

ABSTRACT

We describe a family with thyroid hormone resistance. Juvenile Graves disease was diagnosed in the propositus, an 8-month-old boy. He was initially given propylthiouracil, and at 22 months of age underwent subtotal thyroidectomy. A diagnosis of hyperthyroidism was made in a younger sister at 3 months of age. Because of the unusual occurrence of juvenile Graves disease in two siblings, we evaluated the parents. The mother was euthyroid on physical examination and by thyroid hormone measurements. The father, although clinically euthyroid, had markedly elevated thyroid hormone values. In the three affected members, serum thyrotropin concentrations and results of thyrotropin-releasing hormone infusion tests were inappropriate for the elevated serum thyroid hormone levels. The father was given increasing doses of triiodothyronine. Complete suppression of TRH-induced TSH release did not occur until a daily dose of 300 micrograms triiodothyronine was administered. Furthermore, this large dose of T3 did not produce clinical evidence of hyperthyroidism or result in changes in his systolic ejection time intervals. This family therefore had the unusual feature of clinical heterogeneity. The two children had mainly pituitary resistance to thyroid hormone and were hyperthyroid; the euthyroid father, on the other hand, had generalized tissue resistance to thyroid hormone.


Subject(s)
Hyperthyroidism/genetics , Thyroid Hormones/physiology , Adult , Child, Preschool , Drug Resistance , Female , Humans , Hyperthyroidism/blood , Hyperthyroidism/diagnosis , Infant , Infant, Newborn , Male , Thyroid Hormones/blood , Thyroid Hormones/pharmacology , Thyrotropin/blood , Thyrotropin-Releasing Hormone , Triiodothyronine
SELECTION OF CITATIONS
SEARCH DETAIL
...